news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

Harvard University

Marcie Glicksman, PhD
Dr. Marcie Glicksman is the Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) which is part of the Harvard NeuroDiscovery Center and assistant professor in the Neurology Department at Brigham and Women’s Hospital and Harvard Medical School.  She received a bachelor’s degree from Brown University and a Ph.D. in Neuroscience from Washington University.  Dr. Glicksman has extensive experience in assay development, high throughput screening, and chemical databases, as well as animal pharmacology and preclinical development.  She has been in the field of drug discovery for twenty years, the most recent six years in academics and more than ten years in the pharmaceutical /biotechindustry.  Before joining LDDN, she was at the start-up company, Descartes Therapeutics. Before this, she was Director of Leads Discovery at Cubist leading a group in the development of antibiotics with a structure-based drug design approach using x-ray crystallography and chemical modeling, which resulted in lead molecules suitable for testing in animal models. Before Cubist, she was in Leads Discovery at DuPont-Merck (later DuPont Pharmaceuticals) and Cell Biology at Cephalon, Inc. She led the assay development and screening programs for many cell-based and biochemical assays including a protease project and numerous G-protein coupled receptor projects. She also has led a program for Alzheimer’s and Parkinson’s disease that resulted in co-inventorship of CEP1347, a drug candidate directed at a kinase in Phase III clinical trials.  She was elected in 2005 to the Board of Directors for the non-profit drug discovery organization, the Society for Biomolecular Sciences and served as its Chairman for two years.  She is on the science advisory board for the Alzheimer’s disease foundation (ADDF/ISOA) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for NIH and the Michael J Fox foundation.  She also regularly consults and this has included filing an Investigational New Drug application with the FDA, as well as projects involving the development of new technologies.

The NeuroDiscovery Center's Laboratory for Drug Discovery in Neurodegeneration (LDDN)
The NeuroDiscovery Center's Laboratory for Drug Discovery in Neurodegeneration (LDDN) was established to discover chemical agents from which we and others will develop a new generation of drugs to treat neurodegenerative diseases. To accomplish this goal, LDDN has recruited a permanent staff of industry-seasoned scientists with expertise in assay development, laboratory automation, informatics, and medicinal chemistry, to work in close collaboration with principal investigators from the academic neuroscience community. In this way, LDDN helps transform discoveries in the basic biology of neurodegeneration into opportunities for drug discovery.  The LDDN is a state-of-the-art drug discovery facility with 3,000 sq.ft. of dedicated research space including high content and automated microscopic imaging capabilities. Collaborating with the LDDN can be initiated at any stage and may involve: (1) designing and developing an assay based on the basic science and a hypothesis related to neurodegeneration; (2) miniaturizing an assay specifically for the purposes of high-throughput screening (HTS); (3) conducting a full-scale screen of LDDN's collection of 150,000 drug-like molecules; and (4) optimizing compounds through a program of medicinal chemistry to increase potency, reduce toxicity and to address physical-chemical and pharmacology properties (i.e. pharmacokinetics).  We provide the scientific community with not only the physical resources for drug discovery, but crucially, the intellectual and program management help defining the most promising lines of investigation.   

 
Share This Information